Advertisement

Mycopathologia

, Volume 184, Issue 1, pp 23–33 | Cite as

Prosthetic Joint Infections Caused by Candida Species: A Systematic Review and a Case Series

  • Yoo Ra Lee
  • Hyun Jung Kim
  • Eun Ju Lee
  • Jang Wook Sohn
  • Min Ja Kim
  • Young Kyung YoonEmail author
Original Paper
  • 198 Downloads

Abstract

The purpose of this study was to evaluate the efficacy of echinocandins in the treatment of Candida prosthetic joint infection (PJI) based on published literature and on patients we examined. A structured literature review of multiple databases was conducted to identify patients who received echinocandins for Candida PJIs. Additionally, we describe here the first cases of PJIs due to C. parapsilosis, successfully treated with prolonged anidulafungin therapy. Out of 17 patients, 12 were female and the mean age at diagnosis was 66.0 years. No risk factors associated with Candida PJIs were found in four patients (23.5%). Infection sites included the knee (n = 10, 62.5%), the hip (n = 6, 35.3%) and the shoulder (n = 1, 5.9%). The most frequently isolated Candida species were C. albicans (n = 7, 41.2%) and C. glabrata (n = 7, 41.2%), followed by C. parapsilosis (n = 2, 11.8%) and C. freyschussii (n = 1, 5.9%). All patients were cured with the combination of systemic antifungal therapy and surgical interventions. Two-stage exchange arthroplasty and resection arthroplasty were performed in five and nine patients, respectively. The most frequently used echinocandins were caspofungin (n = 11, 64.7%), followed by anidulafungin (n = 4, 23.5%) and micafungin (n = 2, 11.8%). The median duration (days) of echinocandin therapy was as follows: caspofungin (25.5, range 8–56), micafungin (14.0, range 4–56) and anidulafungin (58, range 14–90). This study supports the effective role of echinocandins, as well as the potential advantage of surgical intervention in the treatment of Candida PJIs. Furthermore, it provides fundamental data on the safety of long-term echinocandin therapy.

Keywords

Echinocandins Candida Infectious arthritis Prosthesis-related infections 

Notes

Acknowledgements

The authors wish to thank Professor Chang Kyu Lee for his careful review of microbiological data of our manuscript.

Compliance with Ethical Standards

Conflict of interest

None of the authors has any potential financial or non-financial conflicts of interests related to this manuscript.

References

  1. 1.
    Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis. 2001;33(Suppl 2):S94–106.CrossRefGoogle Scholar
  2. 2.
    Fitzgerald RH Jr. Infections of hip prostheses and artificial joints. Infect Dis Clin North Am. 1989;3(2):329–38.Google Scholar
  3. 3.
    Dutronc H, Dauchy FA, Cazanave C, Rougie C, Lafarie-Castet S, Couprie B, et al. Candida prosthetic infections: case series and literature review. Scand J Infect Dis. 2010;42(11–12):890–5.CrossRefGoogle Scholar
  4. 4.
    Jakobs O, Schoof B, Klatte TO, Schmidl S, Fensky F, Guenther D, et al. Fungal periprosthetic joint infection in total knee arthroplasty: a systematic review. Orthop Rev (Pavia). 2015;7(1):5623.CrossRefGoogle Scholar
  5. 5.
    Phelan DM, Osmon DR, Keating MR, Hanssen AD. Delayed reimplantation arthroplasty for candidal prosthetic joint infection: a report of 4 cases and review of the literature. Clin Infect Dis. 2002;34(7):930–8.CrossRefGoogle Scholar
  6. 6.
    Gebauer M, Frommelt L, Achan P, Board TN, Conway J, Griffin W, et al. Management of fungal or atypical periprosthetic joint infections. J Arthroplasty. 2014;29(2 Suppl):112–4.CrossRefGoogle Scholar
  7. 7.
    Azzam K, Parvizi J, Jungkind D, Hanssen A, Fehring T, Springer B, et al. Microbiological, clinical, and surgical features of fungal prosthetic joint infections: a multi-institutional experience. J Bone Jt Surg Am. 2009;91(Suppl 6):142–9.CrossRefGoogle Scholar
  8. 8.
    Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1–50.CrossRefGoogle Scholar
  9. 9.
    Tande AJ, Patel R. Prosthetic joint infection. Clin Microbiol Rev. 2014;27(2):302–45.CrossRefGoogle Scholar
  10. 10.
    Cobo F, Rodríguez-Granger J, Sampedro A, Aliaga-Martínez L, Navarro-Marí JM. Candida prosthetic joint infection. A review of treatment methods. J Bone Jt Infect. 2017;2(2):114–21.CrossRefGoogle Scholar
  11. 11.
    Lejko-Zupanc T, Mozina E, Vrevc F. Caspofungin as treatment for Candida glabrata hip infection. Int J Antimicrob Agents. 2005;25(3):273–4.CrossRefGoogle Scholar
  12. 12.
    Dumaine V, Eyrolle L, Baixench MT, Paugam A, Larousserie F, Padoin C, et al. Successful treatment of prosthetic knee Candida glabrata infection with caspofungin combined with flucytosine. Int J Antimicrob Agents. 2008;31(4):398–9.CrossRefGoogle Scholar
  13. 13.
    Bland CM, Thomas S. Micafungin plus fluconazole in an infected knee with retained hardware due to Candida albicans. Ann Pharmacother. 2009;43(3):528–31.CrossRefGoogle Scholar
  14. 14.
    Graw B, Woolson S, Huddleston JI. Candida infection in total knee arthroplasty with successful reimplantation. J Knee Surg. 2010;23(3):169–74.CrossRefGoogle Scholar
  15. 15.
    Springer J, Chatterjee S. Candida albicans prosthetic shoulder joint infection in a patient with rheumatoid arthritis on multidrug therapy. J Clin Rheumatol. 2012;18(1):52–3.CrossRefGoogle Scholar
  16. 16.
    Anagnostakos K, Kelm J, Schmitt E, Jung J. Fungal periprosthetic hip and knee joint infections clinical experience with a 2-stage treatment protocol. J Arthroplasty. 2012;27(2):293–8.CrossRefGoogle Scholar
  17. 17.
    Bartalesi F, Fallani S, Salomoni E, Marcucci M, Meli M, Pecile P, et al. Candida glabrata prosthetic hip infection. Am J Orthop (Belle Mead NJ). 2012;41(11):500–5.Google Scholar
  18. 18.
    Hall RL, Frost RM, Vasukutty NL, Minhas H. Candida glabrata: an unusual fungal infection following a total hip replacement. BMJ Case Rep 2012; 2012.Google Scholar
  19. 19.
    Cobo F, Rodríguez-Granger J, López EM, Jiménez G, Sampedro A, Aliaga-Martínez L, et al. Candida-induced prosthetic joint infection. A literature review including 72 cases and a case report. Infect Dis (Lond). 2017;49(2):81–94.CrossRefGoogle Scholar
  20. 20.
    Carrega G, Cavagnaro L, Basso M, Riccio G, Ronca A, Salomone C, et al. Azole-resistant Candida albicans prosthetic joint infection treated with prolonged administration of anidulafungin and two-stage exchange with implant of a mega-prosthesis. J Chemother. 2017;29(6):386–8.CrossRefGoogle Scholar
  21. 21.
    Geng L, Xu M, Yu L, Li J, Zhou Y, Wang Y, et al. Risk factors and the clinical and surgical features of fungal prosthetic joint infections: a retrospective analysis of eight cases. Exp Ther Med. 2016;12(2):991–9.CrossRefGoogle Scholar
  22. 22.
    Jenny JY, Goukodadja O, Boeri C, Gaudias J. May one-stage exchange for Candida albicans peri-prosthetic infection be successful? Orthop Traumatol Surg Res. 2016;102(1):127–9.CrossRefGoogle Scholar
  23. 23.
    Koutserimpas C, Samonis G, Velivassakis E, Iliopoulou-Kosmadaki S, Kontakis G, Kofteridis DP. Candida glabrata prosthetic joint infection, successfully treated with anidulafungin: a case report and review of the literature. Mycoses. 2018;61(4):266–9.CrossRefGoogle Scholar
  24. 24.
    Harris MC, Pereira GR, Myers MD, Cardin AJ, Razdan B, Pleasure J, et al. Candidal arthritis in infants previously treated for systemic candidiasis during the newborn period: report of three cases. Pediatr Emerg Care. 2000;16(4):249–51.CrossRefGoogle Scholar
  25. 25.
    Weigl JA. Candida arthritis in a premature infant treated successfully with oral fluconazole for six months. Ann Acad Med Singap. 2000;29(2):253–5.Google Scholar
  26. 26.
    Sim JP, Kho BC, Liu HS, Yung R, Chan JC. Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin. Hong Kong Med J. 2005;11(2):120–3.Google Scholar
  27. 27.
    Bajwa S, Kulshrestha A. Fungal infections in intensive care unit: challenges in diagnosis and management. Ann Med Health Sci Res. 2013;3(2):238–44.CrossRefGoogle Scholar
  28. 28.
    Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20(Suppl 6):5–10.CrossRefGoogle Scholar
  29. 29.
    Hatipoglu N, Hatipoglu H. Combination antifungal therapy for invasive fungal infections in children and adults. Expert Rev Anti Infect Ther. 2013;11(5):523–35.CrossRefGoogle Scholar
  30. 30.
    Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115(20):4745–52.CrossRefGoogle Scholar
  31. 31.
    Kullberg BJ, Vasquez J, Mootsikapun P, Nucci M, Paiva JA, Garbino J, et al. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials. J Antimicrob Chemother. 2017;72(8):2368–77.CrossRefGoogle Scholar
  32. 32.
    Kontoyiannis DP, Bassetti M, Nucci M, Capparella MR, Yan JL, Aram J, et al. Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: analysis of pooled data from six prospective clinical studies. Mycoses. 2017;60(10):663–7.CrossRefGoogle Scholar
  33. 33.
    Wang JF, Xue Y, Zhu XB, Fan H. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs. Eur J Clin Microbiol Infect Dis. 2015;34(4):651–9.CrossRefGoogle Scholar
  34. 34.
    Wang JL, Chang CH, Young-Xu Y, Chan KA. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother. 2010;54(6):2409–19.CrossRefGoogle Scholar
  35. 35.
    Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs. 2011;71(1):11–41.CrossRefGoogle Scholar
  36. 36.
    Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014;27(1):68–88.CrossRefGoogle Scholar
  37. 37.
    Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother. 2002;46(6):1773–80.CrossRefGoogle Scholar
  38. 38.
    Simitsopoulou M, Peshkova P, Tasina E, Katragkou A, Kyrpitzi D, Velegraki A, et al. Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates. Antimicrob Agents Chemother. 2013;57(6):2562–70.CrossRefGoogle Scholar
  39. 39.
    Katragkou A, Roilides E, Walsh TJ. Role of echinocandins in fungal biofilm-related disease: vascular catheter-related infections, immunomodulation, and mucosal surfaces. Clin Infect Dis. 2015;61(Suppl 6):S622–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Division of Infectious Diseases, Department of Internal MedicineKorea University College of MedicineSeoulRepublic of Korea
  2. 2.Institute for Evidence-Based MedicineCochrane KoreaSeoulRepublic of Korea
  3. 3.Department of Preventive MedicineKorea University College of MedicineSeoulRepublic of Korea
  4. 4.Medical LibraryKorea University College of MedicineSeoulRepublic of Korea

Personalised recommendations